Qiagen N.V. (QGEN) 22.95 $QGEN
RNA Analysis/Transcriptomics Market - Global Forecast to 2019
M2 - Fri Dec 05, 3:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/ftzhsm/rna) has announced the addition of the "RNA Analysis/Transcriptomics Market by Technology, by Application, by End-User - Global Forecast to 2019" report to their offering. The global transcriptomics market is expected to grow at a CAGR of 13.7% during the forecast period of 2014 to 2019 and is estimated to be worth $3,773.0 million by 2019. The transcriptomics market has blatantly grown in the past few years primarily due to the increasing technological advancements in the field of sequencing technologies in transcriptomics research. Similarly, the increasing government and private funding for research coupled with research and development investments by the biotechnology companies are expected to drive the transcriptomics market. The increasing adoption of transcriptomics in the field of biomarker discovery opens new growth avenues with the rising preference of personalized medicine across the globe. However, the higher investment costs that restrict the adoption of transcriptomics products and dearth of skilled professionals are the factors hampering the growth of this market to a certain extent. The transcriptomics market report covers the transcriptomic technologies, applications and end-users. The technologies market in this report is segmented as microarray, PCR, sequencing technologies which include Sanger sequencing and NGS, and RNAi gene silencing technology. Each of these technologies market is further sub-segmented into reagents, instruments and software. The applications of transcriptomics covered under the scope of this report are clinical diagnostics, drug discovery, and toxicogenomics. The end-users of transcriptomics are pharmaceutical and biotechnology companies, academic research and government institutes, and hospitals and diagnostic centers. This report also discusses the key market drivers, restraints, opportunities, challenges, and trends in the global transcriptomics market and its submarkets. The prominent players in the global trancriptomics market are Affymetrix Inc. (U.S.), Agilent Technologies Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), GE Healthcare (U.S.), Illumina Inc. (U.S.), Qiagen N.V. (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Sigma Aldrich (U.S.), Fluidigm Corporation (U.S.), and Thermofisher Scientific Inc. (U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Transcriptomics Technologies Market, By Type 8 Global Transcriptomics Market, By Application 9 Global Transcriptomics Market, By End User 10 Global Transcriptomics Market, By Geography 11 Company Profiles 12 Competitive Landscape 13 Appendix For more information visit http://www.researchandmarkets.com/research/ftzhsm/rna
FLDM: 27.21 (-0.04), A: 39.72 (-0.90), ILMN: 184.30 (-2.53), QGEN: 22.95 (-0.29), AFFX: 8.94 (-0.36)
QIAGEN to Distribute altona Diagnostic's RealStar® Ebolavirus RT-PCR Kit 1.0, Recently Authorized by the FDA for Emergency Use
PR Newswire - Thu Dec 04, 3:00PM CST
-- New molecular diagnostic test detects but does not differentiate all existing strains of Ebola virus
QGEN: 22.95 (-0.29)
FDA to review AstraZeneca's Iressa NDA
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 10:50AM CST
AZN: 71.80 (-1.80), QGEN: 22.95 (-0.29)
Global Next Generation Sequencing Technologies Market Analysis - Trends & Forecast to 2020
M2 - Mon Nov 24, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnm36r/global_next) has announced the addition of the "Global Next Generation Sequencing Technologies Market Analysis - Trends & Forecast to 2020" report to their offering. The global Next Generation Sequencing market is poised to grow at a CAGR of more than 20% to reach around $5.0 billion by 2020. The NGS market assessment was made based on products, technologies, end users, applications and geography. The NGS products market is further divided into instruments and reagents, services and workflow products. The instruments and consumables is the largest segment with a share of around half of the market in 2013. The fastest growing segment is the services with a highest CAGR during the forecast period. The major players are interested in services segment as it provides additional revenue for the company at the same time, increases the sales of instruments and reagents. NGS technology is segmented into targeted resequencing, whole exome sequencing, RNA sequencing, whole genome sequencing, ChIP sequencing, de novo sequencing and methyl sequencing. Among these targeted re-sequencing technology accounted for the largest share of more than 25% of the technology market in 2013 and is expected to grow at a strong CAGR during the forecast period. Whole genome sequencing is poised to grow at the highest CAGR and expected to reach a share of more than 15% of the total market by 2020. Targeted resequencing and whole genome sequencing technologies are the prospective technologies as various targeted disease based NGS assays and panels are emerging and use of personalized medicine transforms with the understanding of individual's whole genome imprint. Key Topics Covered: 1 Summary 2 Introduction 3 Market Analysis 4 Next Generation Sequencing Market, By Products 5 Global Next Generation Sequencing Market Value And Volume Analysis, By Technology 6 Global Next Generation Sequencing Market, By End Users/Laboratories 7 Global Next Generation Sequencing Market Value And Volume Analysis, By Application 8 Geographic Analysis 9 Competitive Landscape 10 Major Player Profiles - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters Ltd - Genomatix Software Gmbh - Hoffmann-La Roche Ltd. - Illumina, Inc. - Pacific Biosciences Of California Inc. - Qiagen N.V. - Strand Life Sciences Pvt. Ltd. - Thermo Fisher Scientific Inc. For more information visit http://www.researchandmarkets.com/research/pn...lobal_next
PACB: 6.81 (+0.04), A: 39.72 (-0.90), ILMN: 184.30 (-2.53), QGEN: 22.95 (-0.29)
Research and Markets: Global Companion Diagnostics Market Outlook, 2019 - Roche Diagnostics, Abbott Labs, Agilent Technologies , QIAGEN N.V. & Thermo Fisher Scientific Dominate the $8.7 Billion Industry
Business Wire - Mon Nov 24, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/txtn28/companion) has announced the addition of the "Companion Diagnostics Market by Technology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering.
ABT: 43.69 (-0.77), A: 39.72 (-0.90), QGEN: 22.95 (-0.29)
Global Companion Diagnostics Market Outlook, 2019 - Roche Diagnostics, Abbott Labs, Agilent Technologies , QIAGEN N.V. & Thermo Fisher Scientific Dominate the $8.7 Billion Industry
M2 - Mon Nov 24, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/3mrpcr/companion) has announced the addition of the "Companion Diagnostics Market by Technology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering. The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3,136.9 million in 2014, growing at a CAGR of 22.7% during the forecast period (2014 to 2019). Factors such as rising need for personalized medicine in cancer treatment, growing adoption of companion diagnostics by the pharmaceutical industry, support from regulatory authorities, and emerging technologies such as next-generation sequencing (NGS) are expected to boost the global companion diagnostics market. Among technologies, PCR is the most preferred test in the companion diagnostics market, which accounted for a share of 65.5% in 2014. This large share can be attributed to its ease of use, better results, faster turnaround time, and cost-effective solutions. The companion diagnostics market is expected to gain a larger market share in neurology and new oncology applications (leukemia, prostate cancer, and ovarian cancer) due to its efficient detection of biomarkers. Moreover, with the advancement in the bioinformatics field, NGS-based tests have the capability to target multiple genomes simultaneously and are likely to take over the existing technologies in the companion diagnostics market. The need for personalized medicine is increasing and it has gained importance in the research and medical centers, hospitals, and CROs. In the coming years, Asia is expected to be the key growth area in this market. However, growth of this market is hampered by the non-validated home brew tests that account for a large market share due to low costs and minimal approval procedures. Moreover, uncertain reimbursement and coverage policies restrict the growth of the global companion diagnostic market, thus limiting the commercialization process. Scope of the Report Technology - Polymerase Chain Reaction - In-situ hybridization - Immunohistochemistry Application - Breast - Lung cancer End-user - Pharmaceutical Companies - Reference Lab Companies Mentioned - Abbott Laboratories, Inc. - Agilent Technologies, Inc. - Biogenex Laboratories - Biom?rieux - Danaher Corporation - Ge Healthcare - Myriad Genetics, Inc. - Qiagen N.V. - Roche Diagnostics - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/3mrpcr/companion
ABT: 43.69 (-0.77), MYGN: 33.98 (-1.15), A: 39.72 (-0.90), QGEN: 22.95 (-0.29), DHR: 83.76 (-0.19)
Molecular Diagnostics in Infectious Disease Testing 2014
M2 - Thu Nov 20, 9:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/zbf7zn/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing 2014" report to their offering. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - Biocartis - BioHelix Corporation (now part of Quidel) - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Great Basin Corporation - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - SACACE For more information visit http://www.researchandmarkets.com/research/zbf7zn/molecular
GNMK: 13.16 (-0.22), ABT: 43.69 (-0.77), MYGN: 33.98 (-1.15), CPHD: 49.73 (-1.24), ILMN: 184.30 (-2.53), QGEN: 22.95 (-0.29), LMNX: 17.94 (-0.29)
Global PCR Technologies Market - Trends & Forecast to 2020 for the $14 Billion Industry
M2 - Thu Nov 20, 6:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/jwh6f3/global_pcr) has announced the addition of the "Global PCR Technologies Market - Trends & Forecast to 2020" report to their offering. The global PCR market is expected to grow at a CAGR of more than 9% from 2014 to 2020 to reach a market size of $14 billion by the end of 2020 The PCR market is mainly segmented by products, techniques, applications, and end users. The market assessment of the above mentioned segments is made across the geographies such as North America, Europe, Asia-Pacific, LATAM and MENA. Factors such as rising investments in drug discovery technologies and diagnostics, increasing demand for innovative technologies for rapid and accurate diagnosis of life threatening diseases, advanced digital PCR, Patent expiry, increasing applications in the fields of life sciences research, clinical diagnostics and molecular testing are driving the PCR market growth. However, high cost of some of the commercial PCR's, stringent government regulations, emergence of alternate technologies such as Next Generation Sequencing, lack of awareness and shortage of skilled labour are expected to hinder the PCR market growth. The global PCR market based on products is segmented into instruments, reagents and consumables, software and services. Further segmentation of each of these segments is derived across the geographies. Reagents and consumables commanded the largest market growing at a strong CAGR during the forecast period, whereas the services segment is expected to register a high growth rate. PCR market by techniques is categorized into Real Time PCR / qPCR, standard PCR, reverse transcriptase PCR, digital PCR, assembly PCR, multiplex PCR, hot start PCR and others. Real time quantitative PCR accounted for the largest share in 2013 growing strong, whereas digital PCR market is expected to register the highest CAGR of around 13% during the forecast period Scope of the Report Global Polymerase Chain Reaction Market, by Products: - Instruments - Reagents & Consumables - Software - Services Global Polymerase Chain Reaction Market, by Techniques: - Real Time PCR / qPCR - Standard PCR - Digital PCR - Reverse transcriptase PCR - Multiplex PCR - Hot Start PCR - Assembly PCR - Others Global Polymerase Chain Reaction Market, by Applications: - Clinical diagnostics - Industrial applications - Others Global Polymerase Chain Reaction Market, by End users: - Hospitals and laboratories - Pharma & Biotech firms and CRO's - Academia - Others Companies Mentioned - Abbott Laboratories - Becton, Dickinson & Company - Bio-Rad Laboratories - GE Healthcare - Hoffman Roche Diagnostics - Promega Corporation - Qiagen N.V. - Siemens Healthcare - Sigma Aldrich Corporation - Thermofisher Scientific For more information visit http://www.researchandmarkets.com/research/jwh6f3/global_pcr
ABT: 43.69 (-0.77), BDX: 136.99 (-1.03), QGEN: 22.95 (-0.29)
Earnings Look Back: QIAGEN Is Up 0.2% Since Reporting Quarterly Results 2 Weeks Ago (QGEN)
Comtex SmarTrend(R) - Mon Nov 17, 1:37PM CST
Two weeks ago on October 29th, 2014 QIAGEN (NASDAQ:QGEN) reported earnings and analysts, on average, expected earnings of $0.27 on sales of $336.9 million. QIAGEN actually reported earnings of $0.14 per share on sales of $336.5 million, missing EPS estimates by $0.13 and matching revenue estimates. Shares of QIAGEN have climbed from $23.52 to $23.56, representing a gain of 0.2% since the company reported earnings 19 days ago.
QGEN: 22.95 (-0.29)
Qiagen Partners with Novartis for Companion Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 1:20PM CST
Qiagen N.V. (QGEN) has signed a master collaboration agreement with Novartis.
ICUI: 80.95 (-1.04), ILMN: 184.30 (-2.53), QGEN: 22.95 (-0.29), NVS: 93.52 (-0.82)
QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics
PR Newswire - Tue Nov 11, 3:00PM CST
-- Master collaboration agreement is a framework for developing and commercializing QIAGEN companion diagnostics, paired with new or existing products
QGEN: 22.95 (-0.29)
Earnings Look Back: QIAGEN Is Down 0.2% Since Reporting Quarterly Results 1 Week Ago (QGEN)
Comtex SmarTrend(R) - Mon Nov 10, 12:25PM CST
When QIAGEN (NASDAQ:QGEN) reported earnings 12 days ago on October 29th, 2014, analysts, on average, expected the company to report earnings of $0.27 on sales of $336.9 million. The company actually reported EPS of $0.14 on sales of $336.5 million, missing EPS estimates by $0.13 and matching revenue estimates. Since the company's report, shares of QIAGEN have fallen from $23.52 to $23.48, representing a loss of 0.2% in the past 12 days.
QGEN: 22.95 (-0.29)
Update: Qiagen 3rd Quarter 2014 Earnings
Andy Batts - at Seeking Alpha - Thu Nov 06, 4:17PM CST
QGEN: 22.95 (-0.29)
Qiagen NV Growth Prospects Offset Sagging HPV Test Demand
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 31, 8:26AM CDT
Source: Qiagen NV Qiagen NV solutions are used every day by healthcare providers to identify disease and select the best treatment regimens and by researchers to develop next generation medicine. The company's potential growth from the rise of...
QGEN: 22.95 (-0.29)
Qiagen Q3 Earnings, Revenues in Line; Outlook Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:50PM CDT
Qiagen's (QGEN) strategic collaborations, test menu expansions and moderately balanced international expansion will likely drive growth over time.
BIIB: 344.49 (+2.16), HSKA: 15.54 (-0.42), ILMN: 184.30 (-2.53), QGEN: 22.95 (-0.29)
Qiagen NV's (QGEN) CEO Peer Schatz on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 29, 9:12PM CDT
QGEN: 22.95 (-0.29)
Qiagen revises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 6:40PM CDT
QGEN: 22.95 (-0.29)
Qiagen meets 3Q profit forecasts
Automated Insights - Wed Oct 29, 5:57PM CDT
KJ VENLO, Netherlands (AP) _ Qiagen NV (QGEN) on Wednesday reported third-quarter profit of $34.7 million.
QGEN: 22.95 (-0.29)
Qiagen EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 3:18PM CDT
QGEN: 22.95 (-0.29)
QIAGEN Reports Results for Third Quarter and First Nine Months of 2014
PR Newswire - Wed Oct 29, 3:00PM CDT
-- Achieved Q3 2014 targets: Adjusted net sales of $336.8 million (+4% CER); adjusted operating income of $84.8 million, a 25% margin; and adjusted EPS of $0.27
QGEN: 22.95 (-0.29)
RNA Analysis/Transcriptomics Market - Global Forecast to 2019
M2 - Fri Dec 05, 3:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/ftzhsm/rna) has announced the addition of the "RNA Analysis/Transcriptomics Market by Technology, by Application, by End-User - Global Forecast to 2019" report to their offering. The global transcriptomics market is expected to grow at a CAGR of 13.7% during the forecast period of 2014 to 2019 and is estimated to be worth $3,773.0 million by 2019. The transcriptomics market has blatantly grown in the past few years primarily due to the increasing technological advancements in the field of sequencing technologies in transcriptomics research. Similarly, the increasing government and private funding for research coupled with research and development investments by the biotechnology companies are expected to drive the transcriptomics market. The increasing adoption of transcriptomics in the field of biomarker discovery opens new growth avenues with the rising preference of personalized medicine across the globe. However, the higher investment costs that restrict the adoption of transcriptomics products and dearth of skilled professionals are the factors hampering the growth of this market to a certain extent. The transcriptomics market report covers the transcriptomic technologies, applications and end-users. The technologies market in this report is segmented as microarray, PCR, sequencing technologies which include Sanger sequencing and NGS, and RNAi gene silencing technology. Each of these technologies market is further sub-segmented into reagents, instruments and software. The applications of transcriptomics covered under the scope of this report are clinical diagnostics, drug discovery, and toxicogenomics. The end-users of transcriptomics are pharmaceutical and biotechnology companies, academic research and government institutes, and hospitals and diagnostic centers. This report also discusses the key market drivers, restraints, opportunities, challenges, and trends in the global transcriptomics market and its submarkets. The prominent players in the global trancriptomics market are Affymetrix Inc. (U.S.), Agilent Technologies Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), GE Healthcare (U.S.), Illumina Inc. (U.S.), Qiagen N.V. (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Sigma Aldrich (U.S.), Fluidigm Corporation (U.S.), and Thermofisher Scientific Inc. (U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Transcriptomics Technologies Market, By Type 8 Global Transcriptomics Market, By Application 9 Global Transcriptomics Market, By End User 10 Global Transcriptomics Market, By Geography 11 Company Profiles 12 Competitive Landscape 13 Appendix For more information visit http://www.researchandmarkets.com/research/ftzhsm/rna
FLDM: 27.21 (-0.04), A: 39.72 (-0.90), ILMN: 184.30 (-2.53), QGEN: 22.95 (-0.29), AFFX: 8.94 (-0.36)
QIAGEN to Distribute altona Diagnostic's RealStar® Ebolavirus RT-PCR Kit 1.0, Recently Authorized by the FDA for Emergency Use
PR Newswire - Thu Dec 04, 3:00PM CST
-- New molecular diagnostic test detects but does not differentiate all existing strains of Ebola virus
QGEN: 22.95 (-0.29)
FDA to review AstraZeneca's Iressa NDA
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 10:50AM CST
AZN: 71.80 (-1.80), QGEN: 22.95 (-0.29)
Global Next Generation Sequencing Technologies Market Analysis - Trends & Forecast to 2020
M2 - Mon Nov 24, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnm36r/global_next) has announced the addition of the "Global Next Generation Sequencing Technologies Market Analysis - Trends & Forecast to 2020" report to their offering. The global Next Generation Sequencing market is poised to grow at a CAGR of more than 20% to reach around $5.0 billion by 2020. The NGS market assessment was made based on products, technologies, end users, applications and geography. The NGS products market is further divided into instruments and reagents, services and workflow products. The instruments and consumables is the largest segment with a share of around half of the market in 2013. The fastest growing segment is the services with a highest CAGR during the forecast period. The major players are interested in services segment as it provides additional revenue for the company at the same time, increases the sales of instruments and reagents. NGS technology is segmented into targeted resequencing, whole exome sequencing, RNA sequencing, whole genome sequencing, ChIP sequencing, de novo sequencing and methyl sequencing. Among these targeted re-sequencing technology accounted for the largest share of more than 25% of the technology market in 2013 and is expected to grow at a strong CAGR during the forecast period. Whole genome sequencing is poised to grow at the highest CAGR and expected to reach a share of more than 15% of the total market by 2020. Targeted resequencing and whole genome sequencing technologies are the prospective technologies as various targeted disease based NGS assays and panels are emerging and use of personalized medicine transforms with the understanding of individual's whole genome imprint. Key Topics Covered: 1 Summary 2 Introduction 3 Market Analysis 4 Next Generation Sequencing Market, By Products 5 Global Next Generation Sequencing Market Value And Volume Analysis, By Technology 6 Global Next Generation Sequencing Market, By End Users/Laboratories 7 Global Next Generation Sequencing Market Value And Volume Analysis, By Application 8 Geographic Analysis 9 Competitive Landscape 10 Major Player Profiles - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters Ltd - Genomatix Software Gmbh - Hoffmann-La Roche Ltd. - Illumina, Inc. - Pacific Biosciences Of California Inc. - Qiagen N.V. - Strand Life Sciences Pvt. Ltd. - Thermo Fisher Scientific Inc. For more information visit http://www.researchandmarkets.com/research/pn...lobal_next
PACB: 6.81 (+0.04), A: 39.72 (-0.90), ILMN: 184.30 (-2.53), QGEN: 22.95 (-0.29)
Research and Markets: Global Companion Diagnostics Market Outlook, 2019 - Roche Diagnostics, Abbott Labs, Agilent Technologies , QIAGEN N.V. & Thermo Fisher Scientific Dominate the $8.7 Billion Industry
Business Wire - Mon Nov 24, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/txtn28/companion) has announced the addition of the "Companion Diagnostics Market by Technology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering.
ABT: 43.69 (-0.77), A: 39.72 (-0.90), QGEN: 22.95 (-0.29)
Global Companion Diagnostics Market Outlook, 2019 - Roche Diagnostics, Abbott Labs, Agilent Technologies , QIAGEN N.V. & Thermo Fisher Scientific Dominate the $8.7 Billion Industry
M2 - Mon Nov 24, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/3mrpcr/companion) has announced the addition of the "Companion Diagnostics Market by Technology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering. The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3,136.9 million in 2014, growing at a CAGR of 22.7% during the forecast period (2014 to 2019). Factors such as rising need for personalized medicine in cancer treatment, growing adoption of companion diagnostics by the pharmaceutical industry, support from regulatory authorities, and emerging technologies such as next-generation sequencing (NGS) are expected to boost the global companion diagnostics market. Among technologies, PCR is the most preferred test in the companion diagnostics market, which accounted for a share of 65.5% in 2014. This large share can be attributed to its ease of use, better results, faster turnaround time, and cost-effective solutions. The companion diagnostics market is expected to gain a larger market share in neurology and new oncology applications (leukemia, prostate cancer, and ovarian cancer) due to its efficient detection of biomarkers. Moreover, with the advancement in the bioinformatics field, NGS-based tests have the capability to target multiple genomes simultaneously and are likely to take over the existing technologies in the companion diagnostics market. The need for personalized medicine is increasing and it has gained importance in the research and medical centers, hospitals, and CROs. In the coming years, Asia is expected to be the key growth area in this market. However, growth of this market is hampered by the non-validated home brew tests that account for a large market share due to low costs and minimal approval procedures. Moreover, uncertain reimbursement and coverage policies restrict the growth of the global companion diagnostic market, thus limiting the commercialization process. Scope of the Report Technology - Polymerase Chain Reaction - In-situ hybridization - Immunohistochemistry Application - Breast - Lung cancer End-user - Pharmaceutical Companies - Reference Lab Companies Mentioned - Abbott Laboratories, Inc. - Agilent Technologies, Inc. - Biogenex Laboratories - Biom?rieux - Danaher Corporation - Ge Healthcare - Myriad Genetics, Inc. - Qiagen N.V. - Roche Diagnostics - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/3mrpcr/companion
ABT: 43.69 (-0.77), MYGN: 33.98 (-1.15), A: 39.72 (-0.90), QGEN: 22.95 (-0.29), DHR: 83.76 (-0.19)
Molecular Diagnostics in Infectious Disease Testing 2014
M2 - Thu Nov 20, 9:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/zbf7zn/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing 2014" report to their offering. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - Biocartis - BioHelix Corporation (now part of Quidel) - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Great Basin Corporation - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - SACACE For more information visit http://www.researchandmarkets.com/research/zbf7zn/molecular
GNMK: 13.16 (-0.22), ABT: 43.69 (-0.77), MYGN: 33.98 (-1.15), CPHD: 49.73 (-1.24), ILMN: 184.30 (-2.53), QGEN: 22.95 (-0.29), LMNX: 17.94 (-0.29)
Global PCR Technologies Market - Trends & Forecast to 2020 for the $14 Billion Industry
M2 - Thu Nov 20, 6:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/jwh6f3/global_pcr) has announced the addition of the "Global PCR Technologies Market - Trends & Forecast to 2020" report to their offering. The global PCR market is expected to grow at a CAGR of more than 9% from 2014 to 2020 to reach a market size of $14 billion by the end of 2020 The PCR market is mainly segmented by products, techniques, applications, and end users. The market assessment of the above mentioned segments is made across the geographies such as North America, Europe, Asia-Pacific, LATAM and MENA. Factors such as rising investments in drug discovery technologies and diagnostics, increasing demand for innovative technologies for rapid and accurate diagnosis of life threatening diseases, advanced digital PCR, Patent expiry, increasing applications in the fields of life sciences research, clinical diagnostics and molecular testing are driving the PCR market growth. However, high cost of some of the commercial PCR's, stringent government regulations, emergence of alternate technologies such as Next Generation Sequencing, lack of awareness and shortage of skilled labour are expected to hinder the PCR market growth. The global PCR market based on products is segmented into instruments, reagents and consumables, software and services. Further segmentation of each of these segments is derived across the geographies. Reagents and consumables commanded the largest market growing at a strong CAGR during the forecast period, whereas the services segment is expected to register a high growth rate. PCR market by techniques is categorized into Real Time PCR / qPCR, standard PCR, reverse transcriptase PCR, digital PCR, assembly PCR, multiplex PCR, hot start PCR and others. Real time quantitative PCR accounted for the largest share in 2013 growing strong, whereas digital PCR market is expected to register the highest CAGR of around 13% during the forecast period Scope of the Report Global Polymerase Chain Reaction Market, by Products: - Instruments - Reagents & Consumables - Software - Services Global Polymerase Chain Reaction Market, by Techniques: - Real Time PCR / qPCR - Standard PCR - Digital PCR - Reverse transcriptase PCR - Multiplex PCR - Hot Start PCR - Assembly PCR - Others Global Polymerase Chain Reaction Market, by Applications: - Clinical diagnostics - Industrial applications - Others Global Polymerase Chain Reaction Market, by End users: - Hospitals and laboratories - Pharma & Biotech firms and CRO's - Academia - Others Companies Mentioned - Abbott Laboratories - Becton, Dickinson & Company - Bio-Rad Laboratories - GE Healthcare - Hoffman Roche Diagnostics - Promega Corporation - Qiagen N.V. - Siemens Healthcare - Sigma Aldrich Corporation - Thermofisher Scientific For more information visit http://www.researchandmarkets.com/research/jwh6f3/global_pcr
ABT: 43.69 (-0.77), BDX: 136.99 (-1.03), QGEN: 22.95 (-0.29)
Earnings Look Back: QIAGEN Is Up 0.2% Since Reporting Quarterly Results 2 Weeks Ago (QGEN)
Comtex SmarTrend(R) - Mon Nov 17, 1:37PM CST
Two weeks ago on October 29th, 2014 QIAGEN (NASDAQ:QGEN) reported earnings and analysts, on average, expected earnings of $0.27 on sales of $336.9 million. QIAGEN actually reported earnings of $0.14 per share on sales of $336.5 million, missing EPS estimates by $0.13 and matching revenue estimates. Shares of QIAGEN have climbed from $23.52 to $23.56, representing a gain of 0.2% since the company reported earnings 19 days ago.
QGEN: 22.95 (-0.29)
Qiagen Partners with Novartis for Companion Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 1:20PM CST
Qiagen N.V. (QGEN) has signed a master collaboration agreement with Novartis.
ICUI: 80.95 (-1.04), ILMN: 184.30 (-2.53), QGEN: 22.95 (-0.29), NVS: 93.52 (-0.82)
QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics
PR Newswire - Tue Nov 11, 3:00PM CST
-- Master collaboration agreement is a framework for developing and commercializing QIAGEN companion diagnostics, paired with new or existing products
QGEN: 22.95 (-0.29)
Earnings Look Back: QIAGEN Is Down 0.2% Since Reporting Quarterly Results 1 Week Ago (QGEN)
Comtex SmarTrend(R) - Mon Nov 10, 12:25PM CST
When QIAGEN (NASDAQ:QGEN) reported earnings 12 days ago on October 29th, 2014, analysts, on average, expected the company to report earnings of $0.27 on sales of $336.9 million. The company actually reported EPS of $0.14 on sales of $336.5 million, missing EPS estimates by $0.13 and matching revenue estimates. Since the company's report, shares of QIAGEN have fallen from $23.52 to $23.48, representing a loss of 0.2% in the past 12 days.
QGEN: 22.95 (-0.29)
Update: Qiagen 3rd Quarter 2014 Earnings
Andy Batts - at Seeking Alpha - Thu Nov 06, 4:17PM CST
QGEN: 22.95 (-0.29)
Qiagen NV Growth Prospects Offset Sagging HPV Test Demand
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 31, 8:26AM CDT
Source: Qiagen NV Qiagen NV solutions are used every day by healthcare providers to identify disease and select the best treatment regimens and by researchers to develop next generation medicine. The company's potential growth from the rise of...
QGEN: 22.95 (-0.29)
Qiagen Q3 Earnings, Revenues in Line; Outlook Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:50PM CDT
Qiagen's (QGEN) strategic collaborations, test menu expansions and moderately balanced international expansion will likely drive growth over time.
BIIB: 344.49 (+2.16), HSKA: 15.54 (-0.42), ILMN: 184.30 (-2.53), QGEN: 22.95 (-0.29)
Qiagen NV's (QGEN) CEO Peer Schatz on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 29, 9:12PM CDT
QGEN: 22.95 (-0.29)
Qiagen revises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 6:40PM CDT
QGEN: 22.95 (-0.29)
Qiagen meets 3Q profit forecasts
Automated Insights - Wed Oct 29, 5:57PM CDT
KJ VENLO, Netherlands (AP) _ Qiagen NV (QGEN) on Wednesday reported third-quarter profit of $34.7 million.
QGEN: 22.95 (-0.29)
Qiagen EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 3:18PM CDT
QGEN: 22.95 (-0.29)
QIAGEN Reports Results for Third Quarter and First Nine Months of 2014
PR Newswire - Wed Oct 29, 3:00PM CDT
-- Achieved Q3 2014 targets: Adjusted net sales of $336.8 million (+4% CER); adjusted operating income of $84.8 million, a 25% margin; and adjusted EPS of $0.27
QGEN: 22.95 (-0.29)
